Skip to main content
Contact Us
Subscribe
E-Edition
56°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by PharmaTher Holdings Ltd.
PharmaTher Receives US FDA Approval Goal Date for Ketamine
March 11, 2025
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Provides Update on FDA New Drug Application for Ketamine
February 12, 2025
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher CEO Issues Letter to Shareholders
January 06, 2025
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
November 26, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
November 19, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
November 13, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
October 23, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces Update on FDA New Drug Application for Ketamine
September 04, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
CSE:PHRX
LMLLF
PHRRF
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
CSE:PHRX
LMLLF
PHRRF
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
CSE:PHRX
LMLLF
PHRRF
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 10, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
CSE:PHRX
LMLLF
PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 18, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
CSE:PHRX
LMLLF
PHRRF
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 12, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Provides Update for Expected FDA Approval of Ketamine
January 10, 2024
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
September 27, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
September 06, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
July 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
June 27, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
June 20, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Provides Corporate Update
June 12, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
May 02, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
March 29, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
February 07, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
February 02, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
February 01, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
January 18, 2023
From
PharmaTher Holdings Ltd.
Via
GlobeNewswire
Tickers
CSE:PHRM
PHRRF
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.